DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquı́n Mateo, Johann S. de Bono, Emma Hall et al.|New England Journal of Medicine|2015Cited by 2.2k
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)Joaquı́n Mateo, Lajos Pusztai|Annals of Oncology|2018Cited by 774
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trialJoaquı́n Mateo, Johann S. de Bono, Núria Porta et al.|The Lancet Oncology|2019Cited by 643
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Johann S. de Bono, Joaquı́n Mateo et al.|Cancer Discovery|2017Cited by 422
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working GroupM.F. Mosele, Fabrice André, C. Benedikt Westphalen et al.|Annals of Oncology|2024Cited by 343